Avaliação do efeito antitumoral de derivados de Quinazolinas em células de Glioblastoma
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Glioblastoma multiforme (GBM) is a highly invasive and aggressive brain tumor.
Classified as grade 4 malignancy, it is one of the most lethal tumors, with an average
survival of 10 to 20 months after diagnosis. GBM does not respond well to conventional
treatments, making the search for new therapeutic approaches crucial. In this context,
our research group has been investigating the activity of quinazoline-derived
compounds, molecules known for their biological properties, such as antitumor,
antihypertensive, anti-inflammatory activity, kinase inhibition, among others. The
general objective of this study was to evaluate the antitumor effect of KDY23, a
quinazoline derivative, on GBM cells. The organic synthesis and physicochemical
characterization of the synthesized molecules were performed, followed by biological
assays. After treatment with the synthesized molecules, named KDYs, KDY23
significantly reduced the viability of GBM cells at concentrations starting from 10 µM,
standing out as the most promising molecule. Through western blotting assays, the
expression of cleaved caspase-3 and cleaved PARP proteins was observed in the cells
treated with KDY23, indicating that the compound promotes cell death by apoptosis.
To understand the mechanism of action of KDY23, qRT-PCR assays were performed,
revealing that the compound acts on the survival and cell proliferation pathway known
as the EGFR-PI3K/AKT1/mTOR pathway. The results suggest that KDY23 could be a
potential candidate for the development of new therapies against GBM.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

